Sana Biotechnology Inc (SANA) concluded trading on Wednesday at a closing price of $1.81, with 4.56 million shares of worth about $8.26 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -55.75% during that period and on March 26, 2025 the price saw a loss of about -15.81%. Currently the company’s common shares owned by public are about 223.92M shares, out of which, 125.16M shares are available for trading.
Stock saw a price change of -22.65% in past 5 days and over the past one month there was a price change of -30.12%. Year-to-date (YTD), SANA shares are showing a performance of 11.04% which decreased to -80.22% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $1.52 but also hit the highest price of $10.50 during that period. The average intraday trading volume for Sana Biotechnology Inc shares is 7.52 million. The stock is currently trading -27.58% below its 20-day simple moving average (SMA20), while that difference is down -37.27% for SMA50 and it goes to -53.58% lower than SMA200.
Sana Biotechnology Inc (NASDAQ: SANA) currently have 223.92M outstanding shares and institutions hold larger chunk of about 55.52% of that.
The stock has a current market capitalization of $407.29M and its 3Y-monthly beta is at 1.67. It has posted earnings per share of -$1.17 in the same period. It has Quick Ratio of 3.54 while making debt-to-equity ratio of 0.38. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for SANA, volatility over the week remained 10.86% while standing at 10.70% over the month.
Stock’s fiscal year EPS is expected to rise by 20.37% while it is estimated to increase by 6.44% in next year. EPS is likely to grow at an annualized rate of 3.95% for next 5-years, compared to annual growth of -10.60% made by the stock over the past 5-years.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Citizens JMP on March 18, 2025 offering a Mkt outperform rating for the stock and assigned a target price of $5 to it. Coverage by Jefferies stated Sana Biotechnology Inc (SANA) stock as a Buy in their note to investors on March 14, 2025, suggesting a price target of $7 for the stock. Stock get a Buy rating from Rodman & Renshaw on June 26, 2024.
